Aims: In recent years there has been an increase in the number of biomarkers in heart failure(HF). The clinical role for these novel biomarkers in combination is not clear.
Introduction
An accurate means of predicting mortality risk in heart failure (HF) would allow clinicians to have an honest and informed discussion with patients regarding their prognosis (1) . Those at low risk could be reassured. Those at high risk of dying could be considered for complex devices (including an implantable cardioverter-defibrillator -ICD), cardiac transplantation, or optimal end of life care (2) .
In recent years there has been a remarkable increase in the number of biomarkers available in HF (3), many of which have been thought to hold prognostic potential (4, 5) .
Yet understanding of their relevance and clinical value for patients with HF in real world populations remains limited. Different biomarkers represent different pathophysiological pathways. The use of multiple biomarkers (that reflect different pathophysiological processes) in combination may be of greater prognostic value than using them in isolation. Many of these putative prognostic markers have been tested in small, selected populations with limited multivariable analyses. To date, no study has evaluated the prognostic value of multiple novel biomarkers, representing all the known pathophysiological pathways, in combination in a real-life, unselected chronic HF population.
We studied the prognostic value of several contemporary biomarkers, spanning several 
Methods
Our study was approved by the Local Ethics Committee and complied with the Declaration of Helsinki. All patients provided written informed consent.
Study design
The study design has previously been reported (6). Briefly, we enrolled 1003 nearconsecutive patients with decompensated HF from three hospitals and defined HF according to the criteria of the European Society of Cardiology (7). Eligible patients were required to be 18 years or older and an elevated B-type natriuretic peptide (BNP >100pg/ml) was mandatory. The main exclusion criteria were: primary presentation with myocardial infarction (MI), concurrent systemic disease likely to result in reduced life expectancy or cognitive impairment. Attendance for the study visit occurred 1 month post-discharge. Of 1003 patients originally enrolled, 648 patients (65%) attended the study visit. Failure to attend was due to death (n=115, 11%), deterioration in health (n=73, 7%) or withdrawal of consent (n=167, 17%).
Laboratory measurements -biomarkers studied
Whole blood was drawn from venepuncture into serum and plasma vacutainers. Samples were processed immediately by centrifugation at 3000g for 15 minutes and serum and plasma fractions were aliquoted for storage at -80°C until assay. Copeptin, MR-proADM and MR-proANP were measured on an automated BRAHMS Kryptor analyzer (BRAHMS, Hemel Hempstead, UK) with limits of detection 4.8pmol/l, 0.05nmol/l and 6pmol/l, respectively. Assay precision (coefficient of variation [CV] ) ranged between 2.2-3.2%, 3.5-6.1% and 2.1-13.5% for MR-proANP, MR-proADM and copeptin, respectively. Hs-cTnT was measured on an automated e411 (Roche, Burgess Hill, UK), with a limit of detection of 3ng/ml and CV range of 1.2-5.5%. ST2 was measured using an enzyme-linked immunosorbent assay (ELISA) (R&D systems, Oxon, UK), with a limit of sensitivity of 0.1ng/ml and CV range of 4.4-10.6%. Galectin-3 was measured in our laboratory using an ELISA (provided by BG Medicine, MA, USA) according to the manufacturer's instructions with a limit of sensitivity of 1.3ng/ml and CV range of 3.2-6.2%. cFLC were measured by turbidimetry using the Combylite™ immunoassay on a SPAPLUS® automated analyzer (The Binding Site Group, Ltd, Birmingham, UK), with a limit of quantification of 0.63mg/l and CV range of 5.5-14.4%. Cystatin C was measured on a SPAPLUS® automated analyzer (The Binding Site Group, Ltd, Birmingham, UK), with a limit of detection of 0.4mg/l and CV range of 5.4-9.4%. hsCRP was measured using a Siemens immunoassay on a Siemens BN II™ nephelometer, with a limit of detection of 0.03mg/ml and CV range of 2.5-5.7.
Plasma BNP was measured using an Abbott Architect assay (Abbott Diagnostics, Maidenhead, UK). Along with BNP, all other biochemical and hematological assays were performed in local National Health Service laboratories in Glasgow, UK, and these assays all performed adequately in the relevant national external quality assurance schemes.
Left ventricular ejection fraction
Left ventricular ejection fraction (LVEF) was measured by two-dimensional echocardiography and reduced systolic function was defined as LVEF <50% (8).
Analysis was performed offline, using the biplane method of discs (modified Simpson's rule) by a single operator blinded to patient information.
Follow-up
All patients consented to be "flagged" with the Information Services Division (ISD) of the Scottish Health Service for data on in-hospital and out-of hospital deaths, held by the General Register Office for Scotland. The primary outcome measure was all-cause mortality. Model performance was assessed using Harrel's C-statistic (12). The proportional hazards assumption was assessed using Shoenfield residuals. Each biomarker was dichotomized using receiver operating characteristic (ROC) curves with cut-points determined using the Kaplan Meier method (13). Univariate and multivariable analyses were performed as before using the dichotomized results. A p-value d 0.1 was considered significant. The effect of multiple elevated biomarkers was then evaluated for 1, 2 and 3 or more elevated biomarkers using univariate and multivariable analysis. Kaplan-Meier survival curves were constructed to illustrate survival of patients according to number of elevated novel biomarkers, dichotomized from ROC analysis. Curves were compared using the log rank test. All statistical analyses were performed using R version 2.15.0 or above. The net reclassification index (NRI) (14), adapted for use in survival models (15), was used to assess if elevated levels of 3 or more novel biomarkers improved the prediction of outcome, in addition to the multivariable model. Internal validation was performed by bootstrapping, using Somers' Dxy rank correlation as the marker of validation, to evaluate the predictive performance of the data.
Statistical Analysis

Results
Of 648 patients completing the study visit, 628 (97%) had analysis of the entire set of novel biomarkers performed. The mean (SD) age of the overall cohort was 71 (11) years and 367 (58%) were male. The baseline clinical characteristics, including novel biomarker results, are presented in Table 1 for the overall cohort.
Overall survival following hospital admission with decompensated heart failure
The mean (SD) follow-up was 3.2 (1.5) years. Of the 628 patients with novel biomarker measurements, 290 (46%) died during the follow-up period. The multivariable analysis for the base model is shown in Table 2 .
Unadjusted outcomes according to novel biomarker concentration
Elevated concentrations of all of the novel biomarkers were associated with a higher unadjusted risk of mortality ( The multivariable analyses with each biomarker added individually to the baseline model are displayed in Table 4 (the full models are shown in Table 1 of the Appendix). In the base model, almost half of the predefined variables were independent predictors of an increased risk of death with a C-statistic for the overall model of 0.721 (Table 2 ). In the multivariable analyses, MR-proADM, hs-cTnT, ST2, cFLC, hsCRP and cystatin C remained independent predictors of mortality (defined as p d 0.1). Copeptin, MRproANP and galectin-3 failed to add incremental prognostic value to the base model. 
Multivariable analyses using dichotomized biomarkers
Each biomarker was dichotomized using receiver operating characteristic (ROC) curves; the cut-points are displayed in Table 3 . Univariate and multivariable analyses were performed as before using the dichotomized results (Tables 3 and 4 There were many differences in clinical characteristics according to number of biomarkers elevated (Appendix Table 5 ). Compared with patients with no elevated or 1-2 elevated biomarkers, patients with 3 or more elevated biomarkers were older, more often male and to have a previous diagnosis of HF. They were more symptomatic, with a greater proportion of patients in NYHA class III/IV and more had peripheral oedema.
Patients with 3 or more elevated biomarkers also had more comorbidities such as myocardial infarction, hypertension, diabetes mellitus and atrial fibrillation.
Discussion
We compared the prevalence and prognostic significance of a range of novel biomarkers, individually and collectively, in a group of patients recently hospitalized with decompensated HF. Our patients had a high mortality rate, with 46% of the cohort deceased by the end of the follow-up period. The first notable, but perhaps unsurprising, finding was that all of these biomarkers individually were predictors of unadjusted mortality risk in this relatively unselected cohort. However, only half of the novel biomarkers were independent predictors of mortality when added to a multivariable prognostic model containing established predictors of mortality risk, including BNP.
Copeptin, MR-proANP and galectin-3 failed to add any incremental prognostic value to this base model. The second important finding was that, following dichotomization of the novel biomarkers, the presence of at least 3 elevated biomarkers identified patients at greatest risk of death. The predictive value of 3 or more elevated biomarkers remained after adjustment for other prognostic factors in the multivariable model -such patients had more than double the adjusted risk of death compared to patients with no elevation of any of these novel biomarkers. Furthermore, elevation of at least 3 novel biomarkers improved net reclassification in addition to an extensive multivariable model.
Novel biomarkers individually have limited incremental prognostic value
Heart failure is a complex syndrome involving many pathophysiological pathways, the components of which can be represented by various biomarkers. The main recognized pathways are the neurohormonal, cardiomyocyte injury, cardiomyocyte stress, remodelling and inflammatory processes, as well as extra-cardiac influences. To our knowledge this is the first study to study the prognostic value of multiple novel candidate biomarkers together, with representation from all of the main pathophysiological pathways.
The baseline model had reasonably good predictive power (C-statistic higher than 0.7)
prior to the addition of any of the novel biomarkers as continuous variables. Although MR-proADM and ST2 provided some incremental prognostic information to the baseline model, the importance of inflammation and extra-cardiac processes was also apparent with hsCRP and cFLC demonstrating independent predictive value. However, individually, these biomarkers only modestly improved the predictive power of the model. This may suggest that evaluation of one pathophysiological pathway may not give sufficient prognostic information to be clinically valuable (or that particular pathways may be more or less important in particular individuals).
Dichotomized cut-points -similar values to published thresholds of risk
The potential clinical value of the novel biomarkers was more apparent using dichotomized cut-points from the ROC analysis, especially when more than one biomarker was evaluated simultaneously (see below). Dichotomization into low-(0-2 elevated biomarkers) or high-(at least 3 elevated biomarkers) risk groups provided greatest incremental prognostic value statistically, and possibly a more clinically meaningful result for the practicing clinician. The cut-points yielded from ROC analysis were similar to the thresholds of risk that have previously been published for the individual biomarkers. A previous study of copeptin, MR-proADM and MR-proANP in a small group of patients with acute decompensated HF, (n=137), found similar concentrations to the present study for identifying low and high risk of 1 year mortality (16). Our dichotomized cut-point for hs-cTnT (21.9pg/ml) is extremely close to the level (20pg/ml) that has previously been shown to identify patients with acute decompensated HF at greatest risk of all-cause mortality (17). In that study patients hospitalized with HF secondary to acute myocardial infarction were also excluded, akin to our study, and follow-up exceeded one year. A large, multicenter study of patients with chronic systolic HF (18) found median values of ST2 similar to our dichotomized cut-point (27.5ng/ml vs 28.4ng/ml). Patients in the highest tertile (ST2>36.3ng/ml) were at greatest risk of mortality or cardiac transplantation, over a similar median follow-up period to our study.
hs-CRP has recently been studied in a large, randomized controlled clinical trial in acute decompensated HF (19). Interestingly, hs-CRP levels that had increased from baseline during hospitalization to 30 days post-discharge were associated with a greater 180-day mortality but elevated levels during admission were not. Although a threshold of risk for hs-CRP at 30-days post hospitalization is not reported, the median value (4.57mg/l) is close to our dichotomized cut-point (6.0mg/l). We have recently reported the incremental prognostic value of cFLC in HF (20), although little else is known about the potential role of this biomarker in patients with HF.
'The old and the new' -a simple multi-marker approach
An elevation of at least three out of five of the novel biomarkers significant in the dichotomized analysis (MR-proADM, hs-cTnT, ST2, cFLC and hsCRP) provided incremental prognostic value when added to a multivariable model containing established predictors of mortality in patients with HF, including BNP. Few novel markers have previously added incremental predictive information to comprehensive multivariable models containing BNP. Of particular importance in our study was MR-proADM, which was elevated in nearly all (93%) patients at greatest mortality risk (3 or more elevated biomarkers), and hs-cTnT that was elevated in the vast majority of cases (84%); hsCRP was also commonly (in 73%) elevated in these patients, as were cFLCs (70%). As mentioned earlier, individual biomarkers, or clusters of biomarkers, may potentially identify the pathophysiological pathways which are most important in determining outcome in HF. However, hs-cTnT is arguably a non-specific marker of myocyte necrosis that is not specific to any injurious mechanism. The precise source of MR-proADM and stimuli for its production are uncertain, although the major source of this peptide may be the blood vessels.
Potential future role for multiple biomarkers in the management of HF?
All of the biomarkers in this study were measured using simple, readily available assays.
In combination five of the novel biomarkers, as dichotomized variables, were powerful predictors of mortality risk, with an elevation of three or more biomarkers stratifying those at greatest risk. Incorporation of these five biomarkers into the routine blood tests that are regularly measured in patients with HF would help identify those at greatest risk.
This may aid clinicians with the difficult decisions surrounding the management of such high-risk patients. On the other hand, identifying patients with no, or few, elevated biomarkers who are at lower risk may help reassure both clinicians and patients. From a practical perspective, future creation of a single panel assay to measure all five of these novel biomarkers together would be more efficient for the practicing clinician. Finally, the use of these novel biomarkers in any clinical decision making process would first require prospective testing in a randomized controlled clinical trial in a well-defined, representative population of patients with HF.
Study limitations
Only single baseline measurements of the novel biomarkers were available for the patients in this study. Longitudinal monitoring of these biomarkers may be even more useful for risk stratification and identifying patients who remain at particularly high risk.
Our patients were studied one month post-hospitalization for decompensated HF and many of these biomarkers may differ between acutely decompensated and chronically stable patients (and the patients in this study were a survivor cohort). We did not have a validation cohort. Non-fatal outcomes and cause of death were not available.
Conclusions
The novel biomarkers included in this study added little, if any, incremental prognostic 
